Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Arsenault BJ, et al. Among authors: amarenco p. Am J Cardiol. 2014 Apr 15;113(8):1378-82. doi: 10.1016/j.amjcard.2014.01.414. Epub 2014 Feb 1. Am J Cardiol. 2014. PMID: 24582532 Clinical Trial.
High-dose atorvastatin after stroke or transient ischemic attack.
Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Amarenco P, et al. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. N Engl J Med. 2006. PMID: 16899775 Free article. Clinical Trial.
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Sillesen H, et al. Among authors: amarenco p. Stroke. 2008 Dec;39(12):3297-302. doi: 10.1161/STROKEAHA.108.516450. Epub 2008 Oct 9. Stroke. 2008. PMID: 18845807
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial).
Aronow HD, Califf RM, Harrington RA, Vallee M, Graffagnino C, Shuaib A, Fitzgerald DJ, Easton JD, Van de Werf F, Diener HC, Ferguson J, Koudstaal PJ, Amarenco P, Theroux P, Davis S, Topol EJ. Aronow HD, et al. Among authors: amarenco p. Am J Cardiol. 2008 Nov 15;102(10):1285-90. doi: 10.1016/j.amjcard.2008.07.019. Epub 2008 Sep 15. Am J Cardiol. 2008. PMID: 18993142
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A 3rd, Hennerici MG, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Amarenco P, et al. Stroke. 2010 Mar;41(3):426-30. doi: 10.1161/STROKEAHA.109.564781. Epub 2010 Jan 28. Stroke. 2010. PMID: 20110538 Clinical Trial.
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ. Boekholdt SM, et al. Among authors: amarenco p. Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21. Circulation. 2013. PMID: 23965489 Free PMC article.
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Ovbiagele B, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A 3rd, Hennerici MG, Zivin J, Welch KM; SPARCL Investigators. Ovbiagele B, et al. Among authors: amarenco p. J Stroke Cerebrovasc Dis. 2014 Apr;23(4):778-84. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.001. Epub 2014 Feb 24. J Stroke Cerebrovasc Dis. 2014. PMID: 24582273 Clinical Trial.
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.
Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Boekholdt SM, et al. Among authors: amarenco p. J Am Coll Cardiol. 2014 Aug 5;64(5):485-94. doi: 10.1016/j.jacc.2014.02.615. J Am Coll Cardiol. 2014. PMID: 25082583 Free PMC article. Review.
477 results